Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
June 14, 2024 07:50 ET
|
Mereo BioPharma Group plc
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
May 30, 2024 07:30 ET
|
Mereo BioPharma Group plc
LONDON, May 30, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 15, 2024 16:01 ET
|
Mereo BioPharma Group plc
LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its...
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024 07:30 ET
|
Mereo BioPharma Group plc
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
March 27, 2024 16:01 ET
|
Mereo BioPharma Group plc
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively ...
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
March 05, 2024 07:30 ET
|
Mereo BioPharma Group plc
LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
January 08, 2024 07:00 ET
|
Mereo BioPharma Group plc
Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q...
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
October 23, 2023 16:01 ET
|
Mereo BioPharma Group plc
LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an...
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
September 21, 2023 07:00 ET
|
Mereo BioPharma Group plc
LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update
September 07, 2023 07:30 ET
|
Mereo BioPharma Group plc
LONDON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...